Falcone Marco, Russo Alessandro, Iraci Federica, Carfagna Paolo, Goldoni Paola, Vullo Vincenzo, Venditti Mario
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy
Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Antimicrob Agents Chemother. 2015 Oct 19;60(1):252-7. doi: 10.1128/AAC.01927-15. Print 2016 Jan.
We determined the incidence, risk factors, and outcomes of bloodstream infections (BSI) subsequent to Clostridium difficile infection (CDI). We performed a retrospective study of all patients with definite diagnosis of CDI admitted from January 2014 to December 2014 in two large hospitals in Rome. Two groups of patients were analyzed: those with CDI and subsequent BSI (CDI/BSI(+)) and those with CDI and no evidence of primary BSI (CDI/BSI(-)). Data about clinical features, microbiology, treatments, and mortality were obtained. Overall, 393 cases of CDI were included in the final analysis: 72 developed a primary nosocomial BSI, while 321 had CDI without microbiological and clinical evidence of BSI. Etiologic agents of BSI were Candida species (47.3%), Enterobacteriaceae (19.4%), enterococci (13.9%), and mixed infections (19.4%). In multivariate analysis, ribotype 027 status (odds ratio [OR], 6.5), CDI recurrence (OR, 5.5), severe CDI infection (OR, 8.3), and oral vancomycin at >500 mg/day (OR, 3.1) were recognized as factors independently associated with the development of nosocomial BSI. Thirty-day mortality from CDI diagnosis was higher for patients of the CDI/BSI(+) group than for the controls (38.9 versus 13.1%; P < 0.001). Among patients of the CDI/BSI(+) group, mortality attributable to primary BSI was as high as 57%. Our findings suggest that severe CDI is complicated by the development of nosocomial BSI. Candida species and enteric bacteria appear to be the leading causative pathogens and are associated with poor outcomes.
我们确定了艰难梭菌感染(CDI)后血流感染(BSI)的发生率、危险因素及转归。我们对2014年1月至2014年12月在罗马两家大型医院收治的所有确诊CDI患者进行了一项回顾性研究。分析了两组患者:发生CDI且随后发生BSI的患者(CDI/BSI(+))和发生CDI但无原发性BSI证据的患者(CDI/BSI(-))。获取了有关临床特征、微生物学、治疗及死亡率的数据。总体而言,最终分析纳入了393例CDI病例:72例发生了原发性医院获得性BSI,而321例有CDI但无BSI的微生物学及临床证据。BSI的病原体为念珠菌属(47.3%)、肠杆菌科细菌(19.4%)、肠球菌(13.9%)及混合感染(19.4%)。多变量分析显示,核糖体分型027状态(比值比[OR],6.5)、CDI复发(OR,5.5)、严重CDI感染(OR,8.3)及口服万古霉素剂量>500mg/天(OR,3.1)被认为是与医院获得性BSI发生独立相关的因素。CDI/BSI(+)组患者自CDI诊断起30天死亡率高于对照组(38.9%对13.1%;P<0.001)。在CDI/BSI(+)组患者中,原发性BSI所致死亡率高达57%。我们的研究结果提示,严重CDI会并发医院获得性BSI。念珠菌属和肠道细菌似乎是主要致病病原体,且与不良转归相关。